Blood disorders
Lymphoma in Xiamen
厦门 淋巴瘤
1 hospital in Xiamen
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Xiamen may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 29 papers led
Lymphoma in every city Xiamen on the disease page, with the national map
open trials on lymphoma with a hospital in Xiamen
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Xiamen as lead sponsor or study site. 11 of them are led by a hospital in Xiamen. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingGB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT06875063
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingHypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07749365
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingOrelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07778212
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingAxicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06826118
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingClinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06854445
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangsha, Dalian, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Wuhan, Wuhu, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingProspective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
- Phase
- N/A
- Started
- 2024-06
- Posted
- Registry
- NCT06478472
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingZanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06553352
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingLarge Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06651853
Age 18 years to Not stated (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingLenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06151080
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingChidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06151106
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingChidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06158386
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingAZA Combined With RCHOP in P53-mutated DLBCL.
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06158399
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of Xiamen UniversityXiamen
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Xiamen
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Southeast Hospital of Xiamen University中国人民解放军联勤保障部队第九〇九医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital, Xiamen University厦门市妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | none | 0 | 0 | none | none | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Xiamen University厦门大学附属第一医院 | 275 open | 7 | 212 open | 311 open | 284 open | 10 | 541 open | 23 | none | none | none | 2 | 2 | none | 0 | 72 open | none | none | none | 2911 open | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | 2 | none | none | none | 2 | none | 3 | none | none | none | 2 | 0 | none | 3 | none | none | none | none | 1 | none | 1 | 0 | 1 | none | none | none | none | none | |
| Second Affiliated Hospital of Xiamen Medical College厦门市第二医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiamen Cardiovascular Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiamen Cardiovascular Hospital, Xiamen University | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiamen Hospital厦门市中医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Xiamen Humanity Hospital厦门弘爱医院 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiamen Xianyue Hospital厦门市仙岳医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiang'an Hospital, Xiamen University厦门大学附属翔安医院 | none | 7 | none | none | none | none | 23 | none | none | 1 | none | 6 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongshan Hospital, Xiamen University厦门大学附属中山医院 | none | 2 | 27 | 30 | none | 6 | none | none | 0 | none | none | 3 | none | 1 | none | 2 | none | none | none | none | 2 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 0 | none | none | none | none | none | none | 5 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Xiamen.
- Nasopharyngeal carcinoma 275 open
- Oesophageal squamous cell carcinoma 7
- Hepatocellular carcinoma 212 open
- Stomach cancer 311 open
- Lung cancer 284 open
- Pancreatic cancer 10
- Breast cancer 541 open
- Glioma 23
- Osteosarcoma 2
- Gastrointestinal stromal tumour 2
- Ewing sarcoma 0
- Multiple myeloma 72 open
- Lymphoma 2911 open
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 0
- Scoliosis 2
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 3
- Duchenne muscular dystrophy 2
- Behçet disease 0
- IgA nephropathy 3
- Primary sclerosing cholangitis 1
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 0
- Hereditary angioedema 1
- Oesophageal squamous cell carcinoma 2
- Hepatocellular carcinoma 27
- Stomach cancer 30
- Pancreatic cancer 6
- Hepatoblastoma 0
- Osteosarcoma 3
- Neuroblastoma 1
- Multiple myeloma 2
- Beta thalassaemia 2
- Neuromyelitis optica spectrum disorder 0
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 0
- IgA nephropathy 5
- Primary biliary cholangitis 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Xiamen on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.